Covaxin shows 78% overall interim efficacy, 100% efficacy against severe Covid:Bharat Biotech & ICMR
HYDERABAD: The developers of indigenous Covid-19 vaccine Covaxin, Bharat Biotech and Indian Council of Medical Research, on Wednesday said that Covaxin has shown an overall interim clinical efficacy of 78% and a 100% efficacy against severe Covid-19 disease.
The efficacy was announced on the basis of second interim analysis after more than 87 symptomatic cases of Covid-19 were reported among the Phase 3 trial volunteers of Covaxin. In the first interim analysis, the results of which were unveiled in early March, Bharat Biotech and ICMR had declared an efficacy of nearly 81%.
“Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% against mild, moderate, and severe Covid-19 disease. The efficacy against severe Covid-19 disease was 100%, with an impact on reduction in hospitalisations. The efficacy against asymptomatic Covid-19 infection was 70%, suggesting decreased transmission in Covaxin recipients,” they said in a joint statement.
Read More at https://timesofindia.indiatimes.com/india/covaxin-shows-78-overall-interim-efficacy-100-efficacy-against-severe-covid-bharat-biotech-icmr/articleshow/82178824.cms